← Back to Search

Chemotherapy

Chemotherapeutic agent A (Docetaxel) for Lung Cancer

Phase 2
Waitlist Available
Led By Steven Osguthorpe, ND
Research Sponsored by Optimal Health Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up once a week for 3 months
Awards & highlights

Study Summary

This trial will test whether a natural supplement can help cancer patients manage the side effects of chemotherapy.

Eligible Conditions
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~once a week for 3 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and once a week for 3 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PROMIS (Patient-Reported Outcomes Measurement Information System) Global 10 Health Questionnaire to assess change from baseline.
Symptom Assessment Questionnaire to assess change from baseline.
Secondary outcome measures
Cancer antigens blood markers to assess change from baseline.

Trial Design

9Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Chemotherapeutic agent C (Docetaxel)Experimental Treatment1 Intervention
The patients with prostate cancer will receive Chemotherapeutic agent C
Group II: Chemotherapeutic agent B (Cisplatin)Experimental Treatment1 Intervention
The patients with lung cancer will receive Chemotherapeutic agent B
Group III: Chemotherapeutic agent A (Docetaxel)Experimental Treatment1 Intervention
The patients with breast cancer will receive chemotherapeutic agent A
Group IV: Chemotherapeutic agent A (Docetaxel) plus RaproCellActive Control1 Intervention
The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.
Group V: Chemotherapeutic agent B (Cisplatin) plus RaproCellActive Control1 Intervention
The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.
Group VI: Chemotherapeutic agent C plus (Docetaxel) RaproCellActive Control1 Intervention
The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.
Group VII: Chemotherapeutic agent B (Cisplatin) plus placeboPlacebo Group1 Intervention
The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.
Group VIII: Chemotherapeutic agent A (Docetaxel) plus placeboPlacebo Group1 Intervention
The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.
Group IX: Chemotherapeutic agent C (Docetaxel) plus placeboPlacebo Group1 Intervention
The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).
2021
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

Optimal Health ResearchLead Sponsor
7 Previous Clinical Trials
705 Total Patients Enrolled
Steven Osguthorpe, NDPrincipal InvestigatorOptimal Health Research
3 Previous Clinical Trials
395 Total Patients Enrolled
EA Jeppsen, MDStudy ChairOptimal Health Clinic
1 Previous Clinical Trials
160 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What diseases has Docetaxel RaproCell been found to effectively address?

"Clinicians often employ Docetaxel (Chemotherapeutic Agent C Plus/RaproCell) to treat advanced directives, and it may also be helpful for patients experiencing brca1 gene mutation, neoplasm metastasis or metastatic bladder cancer."

Answered by AI

What is the current participant count for this trial's enrollment?

"At this stage, the trial is no longer accepting new participants. It was first submitted to clinicaltrials.gov on January 20th 2021 and most recently updated October 18th 2022. For those looking for alternative studies involving breast cancer, there are 3005 active trials recruiting patients; 933 of them involve Chemotherapeutic agent C plus (Docetaxel) RaproCell."

Answered by AI

What potential adverse effects should be considered when using the combination of Chemotherapeutic agent C plus (Docetaxel) RaproCell?

"Our team at Power assigned Chemotherapeutic agent C plus (Docetaxel) RaproCell a rating of 2, meaning that data exists to back its safety but there is not yet any proof for efficacy."

Answered by AI

Is it possible for me to become a participant in this clinical examination?

"Eligibility criteria for this clinical trial include being 25 to 75 years old and having a diagnosis of breast cancer. Ninety applicants are expected to be admitted into the trial."

Answered by AI

Are enrollments still open for this experiment?

"If we consult clinicaltrials.gov, it is apparent that this medical trial has ceased enrolling patients as the last edit was on October 18th 2022. Nevertheless, there are 3938 other active studies in need of participants at present."

Answered by AI

Are there any other studies that have explored the efficacy of combining Docetaxel and RaproCell?

"Presently, there are 933 clinical trials exploring the effectiveness of Chemotherapeutic agent C plus (Docetaxel) RaproCell in phase 3 with many studies based out of Shanghai. Additionally, 61 437 research centres offer data collection for this treatment around the world."

Answered by AI

Does this clinical trial have an age cutoff, and if so what is the maximum age?

"Eligible participants in this clinical trial must be aged between 25 and 75 years of age. There are 207 studies which involve those younger than 18, while 3808 trials cater to seniors who exceed the 65-year mark."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.
2021. "A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05137067.
~21 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top